Protara Therapeutics, Inc. (TARA): Capital Expenditures
$94.0K
Year ended 2025-12-31
$360.0K
Trailing 12 months to 2026-06-30
-7.8%
3-year compound annual growth
-36.1%
5-year compound annual growth
-7.2%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $94.0K | +49.2% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $63.0K | +40.0% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $45.0K | -62.5% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $120.0K | -79.9% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $596.0K | -32.6% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $884.0K | +86.1% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $475.0K | +299.2% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $119.0K | +240.0% | 2020-03-20, From 2018-01-01 |
| 2017-12-31 | $35.0K | -87.1% | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $271.0K | +36.9% | 2019-03-13, From 2016-01-01 |
| 2015-12-31 | $198.0K | +288.2% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $51.0K | +410.0% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $10.0K | -85.1% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $67.0K | n/a | 2015-03-20, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $94.0K | +49.2% |
| Instil Bio, Inc. (TIL) | 2024-12-31 | $0 | -100.0% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $25.0K | -43.2% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $1.49M | +60.5% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $4.41M | +15.2% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $1.15M | +76.3% |
Compare TARA, TIL, CMPX, MGX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗